Eli Lilly raises annual profit forecast on sustained weight-loss drug demand

Published: 2026-04-30 07:46:45 ET LLY

Published on 04/30/2026 at 07:46 am EDT

April 30 (Reuters) - Eli Lilly raised its annual profit forecast on Thursday, banking on strong demand for its weight-loss and diabetes drugs Zepbound and Mounjaro.

Lilly expects to earn $35.50 to $37.00 per share on an adjusted basis this year, compared to its prior view of $33.50 to $35 per share profit.

Analysts were expecting a profit of $34.55 per share for 2026, according to data compiled by LSEG.

(Reporting by Christy Santhosh and Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)